tiprankstipranks
Advertisement
Advertisement
Kura Oncology: Buy Rating Reiterated as Early Darlifarnib/Adagrasib Data Support Favorable Risk-Reward and $40 Price Target Maintained
PremiumRatingsKura Oncology: Buy Rating Reiterated as Early Darlifarnib/Adagrasib Data Support Favorable Risk-Reward and $40 Price Target Maintained
15d ago
Kura Oncology Earnings Call Signals Early Launch Strength
Premium
Company Announcements
Kura Oncology Earnings Call Signals Early Launch Strength
18d ago
Kura Oncology Earnings Call Highlights Comzifty Momentum
Premium
Company Announcements
Kura Oncology Earnings Call Highlights Comzifty Momentum
24d ago
Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating
PremiumRatingsKura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating
2M ago
Kura Oncology reports results from ongoing FIT-001 clinical trial
Premium
The Fly
Kura Oncology reports results from ongoing FIT-001 clinical trial
2M ago
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
Premium
Market News
3 High-Risk, High-Reward Stocks to Buy Now for Explosive Upside, According to Analysts – 4/16/2026
2M ago
Kura Oncology price target raised to $30 from $29 at BofA
PremiumThe FlyKura Oncology price target raised to $30 from $29 at BofA
3M ago
Kura Oncology price target lowered to $36 from $38 at Wedbush
Premium
The Fly
Kura Oncology price target lowered to $36 from $38 at Wedbush
3M ago
Kura Oncology reports inducement grants under Nasdaq listing rule
Premium
The Fly
Kura Oncology reports inducement grants under Nasdaq listing rule
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100